
The FDA’s new CBER Safety Council separates post-market biologics safety review from approvals, raising oversight for cell and gene therapy developers.
Big Pharma?s Manufacturing Strategy: What is the Next Move?
over 16 years ago
A Commendable Cleanroom Compendiumover 16 years ago
Adopting Serializationover 16 years ago
Manufacturing Failures Place GMP Compliance in Spotlightover 16 years ago
An Ounce of Preventionover 16 years ago
Turning a Blind Eyeover 16 years ago
Report from Asiaover 16 years ago
Q&A with Jerry Jost




